rs28935493
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PM2PM5PP3_StrongPP5_Very_Strong
The NM_000169.3(GLA):c.1025G>A(p.Arg342Gln) variant causes a missense change. The variant allele was found at a frequency of 0.0000089 in 112,349 control chromosomes in the GnomAD database, with no homozygous occurrence. There are no hemizygote samples in GnomAD. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R342P) has been classified as Likely pathogenic.
Frequency
Consequence
NM_000169.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 16 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
GLA | NM_000169.3 | c.1025G>A | p.Arg342Gln | missense_variant | 7/7 | ENST00000218516.4 | NP_000160.1 | |
RPL36A-HNRNPH2 | NM_001199973.2 | c.300+2617C>T | intron_variant | NP_001186902.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
GLA | ENST00000218516.4 | c.1025G>A | p.Arg342Gln | missense_variant | 7/7 | 1 | NM_000169.3 | ENSP00000218516 | P1 |
Frequencies
GnomAD3 genomes AF: 0.00000890 AC: 1AN: 112349Hom.: 0 Cov.: 24 AF XY: 0.00 AC XY: 0AN XY: 34507
GnomAD4 exome Cov.: 31
GnomAD4 genome AF: 0.00000890 AC: 1AN: 112349Hom.: 0 Cov.: 24 AF XY: 0.00 AC XY: 0AN XY: 34507
ClinVar
Submissions by phenotype
Fabry disease Pathogenic:6
Pathogenic, criteria provided, single submitter | clinical testing | Human Genome Sequencing Center Clinical Lab, Baylor College of Medicine | Oct 15, 2017 | A hemizygous c.1025G>A (p.R342Q) pathogenic variant in the GLA gene was detected in this individual. This variant has been previously reported in patients with Fabry disease (PMID, 11531972, 18424138, 24626659, 2458695). Defects in GLA are the cause of Fabry disease [MIM:301500], an X-linked inborn error of glycosphingolipid catabolism resulting from deficient or absent activity of the lysosomal enzyme alpha-galactosidase A. Studies characterizing the effect of the c.1025G>A (p.R342Q) on GLA function have shown impaired GLA activity (PMID, 21598360, 23935525). Therefore, this variant is classified as a pathogenic variant in accordance with ACMG guidelines. - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 22, 2023 | This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 342 of the GLA protein (p.Arg342Gln). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with Fabry disease (PMID: 8012363, 24626659). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 10742). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt GLA protein function with a positive predictive value of 80%. Experimental studies have shown that this missense change affects GLA function (PMID: 21598360, 23935525). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Jul 01, 2001 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | May 04, 2021 | Variant summary: GLA c.1025G>A (p.Arg342Gln) results in a conservative amino acid change located in the Alpha galactosidase A, C-terminal beta-sandwich domain of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 178226 control chromosomes. c.1025G>A has been reported in the literature in multiple individuals affected with Fabry Disease (example, Pasqualim_2014, Turaca_2012, Vedder_2008, Echevarria_2015, Hulkova_2010). These data indicate that the variant is very likely to be associated with disease. The variant has been shown to have significantly reduced GLA activity in both patients and in vitro studies (example, Vedder_2008, Wu_2011). Three clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Jul 15, 2021 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Oct 25, 2021 | - - |
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Oct 03, 2017 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | May 12, 2022 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at